When would you consider glucocorticoids as adjunctive therapy for for community-acquired pneumonia outside of the ICU setting?

Thank you for bringing this new study to my attention; I hadn't seen it yet.

After reviewing the article, my practice regarding steroids remains unchanged. While the trial was well-executed, and it is laudable to see such research coming out of a limited-resource setting, that environment differs si...

We consider glucocorticoids for patients with severe community-acquired pneumonia. This is supported by the CAPE-COD trial and the Society of Critical Care Medicine (SCCM) guidelines, which provide moderate-certainty evidence showing reduced mortality (relative risk [RR] 0.62, 95% confidence interva...